You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and related notes, included in our Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report includes forward-looking statements that involve risks and uncertainties, such as statements of our plans, strategies, objectives, expectations, and intentions. See "Special Note Regarding Forward-Looking Statements" and "Risk Factors" for a discussion of forward-looking statements and important factors that could cause actual results to differ materially from the results described in or implied by these forward-looking statements.
Overview
Our goal is to develop "pan-variant" kinase inhibitors-inhibitors that target all major cancer causing and drug resistance mutations in clinically significant protein kinases. We believe that truly pan-variant inhibitors are required to effectively inhibit the heterogeneous mix of resistance mutations found in patients, and may also suppress the emergence of new mutations when used in earlier lines of therapy. To develop such inhibitors, we deploy our novel predictive resistance assay, or PRA, a highly differentiated cell-based method for testing TKIs that we believe is predictive for "pan-ness."
Our lead product candidate, THE-630, is a pan-variant inhibitor of all major
classes of activating and resistance mutations of the KIT kinase, or a pan-KIT
inhibitor, for the treatment of gastrointestinal stromal tumors, or GIST, a type
of cancer most often characterized by oncogenic activation of KIT. In
The FDA has granted orphan drug designation to THE-630 for the treatment of GIST.
Our second program is THE-349, a fourth-generation inhibitor of epidermal growth factor receptor, or EGFR, inhibitor program in non-small cell lung cancer, or NSCLC. THE-349 is designed to address treatment resistance to existing EGFR inhibitors by targeting the common activating mutations in exons 19 and 21 alone or in combination with the most frequently observed resistance mutations, T790M and C797X. Preclinical characterization of THE-349 as a fourth-generation EGFR, central nervous system, or CNS active, and mutant-selective inhibitor with potent activity against single-, double-, and triple-mutant EGFR variants, including T790M and C797X, was shared in a poster presentation at the 34th EORTC-NCI-AACR, or ENA,
19 Table of Contents
Symposium in
In addition to our lead programs, we have selectively prioritized additional small molecule research programs with established targets, following an assessment of unmet medical need. We intend to prioritize the first of our discovery programs, which is in lead optimization, by the end of 2022.
Since our inception in
We have incurred significant operating losses since inception. Our ability to
generate product revenue sufficient to achieve profitability will depend heavily
on the successful development and eventual commercialization of one or more
product candidates. Our net losses were
? advance the clinical development of THE-630;
? advance THE-349 and other compounds we may develop in the future from discovery
through preclinical development and clinical trials;
? seek marketing approvals for any product candidates that successfully complete
clinical trials;
? obtain, expand, maintain, defend and enforce our intellectual property
portfolio;
? hire additional clinical, regulatory and scientific personnel;
? ultimately establish a sales, marketing and distribution infrastructure to
commercialize any products for which we may obtain marketing approval;
? establish agreements with contract research organizations, or CROs, and
contract manufacturing organizations, or CMOs; and
add operational, legal, compliance, financial and management information
? systems and personnel to support our research, product development and future
commercialization efforts, as well as to support our operations as a public
company.
Our net losses may fluctuate significantly from period to period, depending on the timing of expenditures related to our research and development activities.
We will not generate revenue from product sales unless and until we successfully complete clinical development and obtain regulatory approval for a product candidate. In addition, if we obtain regulatory approval for a product candidate and do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to developing our commercialization capability to support product sales, marketing, manufacturing and distribution activities.
20 Table of Contents
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings or other capital sources, which could include collaborations, strategic alliances or licensing arrangements. We may be unable to raise additional funds or enter into such arrangements when needed, on favorable terms, or at all. Our failure to raise capital or enter into such agreements as, and when, needed, could have a material adverse effect on our business, results of operations, and financial condition, including requiring us to have to delay, reduce or eliminate product development or future commercialization efforts.
Because of the numerous risks and uncertainties associated with development of targeted oncology therapies, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. We will need to generate significant revenue to achieve profitability, and we may never do so. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
As of
Impact of COVID-19 on Our Business
The COVID-19 pandemic continues to evolve, and we will continue to monitor the COVID-19 situation, including the resurgence of cases relating to the spread of new variants. The extent of the impact of the COVID-19 pandemic on our business, operations and development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on our CMOs, CROs, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. To the extent possible, we are conducting business as usual. We will continue to actively monitor the rapidly evolving situation related to COVID-19 and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business. At this point, the extent to which the COVID-19 pandemic may affect our business, operations and development timelines and plans, including the resulting impact on our expenditures and capital needs, remains uncertain and is subject to change.
Initial Public Offering
On
21
Table of Contents
Components of Our Results of Operations
Revenue
We have not generated any revenue since our inception and do not expect to generate any revenue from the sale of products or from other sources in the near future, if at all. If our development efforts for our product candidates, THE-630, THE-349, or any other product candidates that we may develop in the future are successful and result in marketing approval or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from such collaboration or license agreements.
Operating Expenses
Research and Development Expenses
Research and development expenses account for a significant portion of our operating expenses and consist primarily of costs incurred in connection with the discovery and preclinical development of our potential development candidates, and include:
? salaries, benefits, stock-based compensation and other related costs for
individuals involved in research and development activities;
external research and development expenses incurred under agreements with CROs
? and consultants that conduct our preclinical studies and other scientific
development services;
? costs incurred under agreements with CMOs for manufacturing material for our
preclinical studies and planned clinical trials; and
? costs related to compliance with regulatory requirements.
We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors or our estimate of the level of service that has been performed at each reporting date. Payments for these external development activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our condensed consolidated financial statements as prepaid expenses or accrued expenses. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized, even when there is no alternative future use for the research and development. The capitalized amounts are expensed as the related goods are delivered or the services are performed.
A significant portion of our research and development costs have been external costs, which we track after a clinical product candidate has been identified. We utilize third-party contractors for our research and development activities and CMOs for our manufacturing activities and we do not have our own laboratory or manufacturing facilities. Therefore, we have no material facilities expenses attributed to research and development. Our internal research and development costs are primarily personnel-related costs and other indirect costs.
Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase for the foreseeable future as we advance clinical development of our product candidates, THE-630, THE-349, and continue to discover and develop additional product candidates, expand our headcount and maintain, expand and enforce our intellectual property portfolio. If any product candidates enter into later stages of clinical development, they will generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. There are numerous factors associated with the successful
22
Table of Contents
development and commercialization of any product candidates we may develop in the future, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. Additionally, future commercial and regulatory factors beyond our control will impact our clinical development program and plans.
The successful development of our current product candidates, THE-630, THE-349, or any product candidates we may develop in the future is highly uncertain. Therefore, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development and commercialization of THE-630, THE-349 and any other product candidates we may develop. We are also unable to predict when, if ever, material net cash inflows will commence from the sale of any current or future product candidate, if approved. This is due to the numerous risks and uncertainties associated with product development, including the uncertainty of:
? the timing and progress of preclinical and clinical development activities;
? the number and scope of preclinical and clinical programs we decide to pursue;
? our ability to maintain our current research and development programs and to
establish new programs;
? successful patient enrollment in, and the initiation and completion of,
clinical trials;
the successful completion of clinical trials with safety, tolerability and
? efficacy profiles that are satisfactory to the FDA or any comparable foreign
regulatory authority;
? the timing, receipt and terms of any marketing approvals from applicable
regulatory authorities;
? our ability to establish new licensing or collaboration arrangements;
? the performance of our future collaborators, if any;
our ability to establish arrangements with third-party manufacturers for the
? clinical supply of our product candidates and commercial supply of products
that receive marketing approval, if any;
? development and timely delivery of commercial-grade drug formulations that can
be used in our planned clinical trials and for commercialization;
? obtaining, maintaining, defending and enforcing patent claims and other
intellectual property rights;
? commercializing product candidates, if approved, whether alone or in
collaboration with others; and
? maintaining a continued acceptable safety profile of the product candidates
following approval.
Any changes in the outcome of any of these variables with respect to the
development of THE-630, THE-349 or any other future product candidates in
preclinical and clinical development could mean a significant change in the
costs and timing associated with the development of these product candidates.
For example, if the FDA or another regulatory authority were to delay our
planned start of clinical trials or require us to conduct clinical trials or
other testing beyond those that we currently expect, or if we experience
significant delays in enrollment in any clinical trials following the
23
Table of Contents
General and Administrative Expenses
General and administrative expenses consist primarily of personnel-related expenses, including salaries, benefits, and stock-based compensation expenses for personnel in executive, finance, accounting, human resources and other administrative functions. Other significant general and administrative expenses include legal fees relating to patent, intellectual property and corporate matters, and fees paid for accounting, consulting and other professional services, and expenses for rent, insurance and other operating costs.
We anticipate that our general and administrative expenses will increase in the
future as our business expands to support our continued research and development
activities, including any future clinical trials. These increases will likely
include increased costs related to the hiring of additional personnel and fees
to outside consultants, among other expenses. We also anticipate increased
expenses associated with being a public company, including costs for audit,
legal, regulatory and tax-related services related to compliance with the
rules and regulations of the
We do not believe that inflation has had a material effect on our business. However, if our costs, in particular costs related to clinical trial expenses, preclinical expenses and/or employee-related expenses, were to become subject to significant inflationary pressures, it may adversely impact our business, operating results and financial condition.
Other Income, Net
Other income, net primarily consists of interest income, which is earned on cash equivalents that generate interest on a monthly basis, and short-term and long-term investments.
Results of Operations
Comparison of the Three Months Ended
The following table summarizes our results of operations for the three months
ended
THREE MONTHS ENDED SEPTEMBER 30, 2022 2021 CHANGE
Operating expenses:
Research and development
1,203 2 1,201 Total other income, net 1,203 2 1,201 Net loss$ (14,745) $ (7,372) $ (7,373) 24 Table of Contents
Research and Development Expenses
The following table summarizes our research and development expenses for the
three months ended
THREE MONTHS ENDED SEPTEMBER 30, 2022 2021 CHANGE Pan-KIT inhibitor program (THE-630)$ 4,028 $ 3,929 $ 99
Fourth-generation EGFR inhibitor program (THE-349) 2,940 300 2,640 Discovery programs
4,455 767 3,688$ 11,423 $ 4,996 $ 6,427
The increase in research and development expenses was primarily attributable to the following:
a
decrease in preclinical costs of
? in clinical costs, including CRO and other clinical trial services costs of
the ongoing phase 1/2 clinical trial, and increases in salary and benefit
related expenses of
a
? increase in CRO expenses of
increase in stock-based compensation expense of
in salary and benefit related expenses of
a
? including an increase in CRO expenses of
stock-based compensation expense of
benefit related expense of
General and Administrative Expenses
The following table summarizes our general and administrative expenses for the
three months ended
THREE MONTHS ENDED SEPTEMBER 30, 2022 2021 CHANGE Personnel-related expenses (including stock-based compensation)$ 2,657 $ 1,502 $ 1,155 Facilities and supplies 126 64 62 Legal and professional fees 1,418 372 1,046 Other expenses 324 440 (116)$ 4,525 $ 2,378 $ 2,147
The increase in general and administrative expenses was primarily attributable to the following:
a
? in headcount, including an increase in stock-based compensation expense of
million, and an increase in salary and benefit related expense of
partially offset by a decrease in recruiting expense of
25 Table of Contents
a
? increased legal and audit expenses, insurance and other costs associated with
operating as a public company and to support our growing organization.
Total Other Income, Net
Total other income, net, was
Comparison of the Nine Months Ended
The following table summarizes our results of operations for the nine months
ended
NINE MONTHS ENDED SEPTEMBER 30, 2022 2021 CHANGE Operating expenses: Research and development$ 25,315 $ 13,306 $ 12,009 General and administrative 13,292 5,371 7,921 Total operating expenses 38,607 18,677 19,930 Loss from operations (38,607) (18,677) (19,930) Other income, net 1,716 25 1,691 Total other income (expense), net 1,716 25 1,691 Net loss$ (36,891) $ (18,652) $ (18,239)
Research and Development Expenses
The following table summarizes our research and development expenses for the
nine months ended
NINE MONTHS ENDED SEPTEMBER 30, 2022 2021 CHANGE Pan-KIT inhibitor program (THE-630)$ 9,770 $ 10,972 $ (1,202)
Fourth-generation EGFR inhibitor program (THE-349) 7,269 929 6,340 Discovery programs
8,276 1,405 6,871$ 25,315 $ 13,306 $ 12,009
The increase in research and development expenses was primarily attributable to the following:
a
decrease in preclinical costs of
? in clinical costs, including CRO and other clinical trial services costs of
phase 1/2 clinical trial, and increases in salary and benefit related expenses
of
26 Table of Contents
a
? increase in CRO expenses of
increase in stock-based compensation expense of
in allocated salary and benefit related expenses of
a
? including an increase in CRO expenses of
stock-based compensation expense of
benefit related expense of
General and Administrative Expenses
The following table summarizes our general and administrative expenses for the
nine months ended
NINE MONTHS ENDED SEPTEMBER 30, 2022 2021 CHANGE Personnel-related expenses (including stock-based compensation)$ 7,641 $ 2,829 $ 4,812 Facilities and supplies 416 100 316 Legal and professional fees 4,401 1,780 2,621 Other expenses 834 662 172$ 13,292 $ 5,371 $ 7,921
The increase in general and administrative expenses was primarily attributable to the following:
a
? in headcount, including an increase in stock-based compensation expense of
million, and an increase in salary and benefit related expense of
partially offset by a decrease in recruiting expense of
a
? increased legal and audit expenses, insurance and other costs associated with
operating as a public company and to support our growing organization.
Total Other Income, Net
Total other income, net, was
Liquidity and Capital Resources
Sources of Liquidity
Since our inception, we have incurred significant losses in each period and on
an aggregate basis. We have not yet commercialized any product candidates, and
we do not expect to generate revenue from sales of any product candidates or
from other sources for several years, if at all. As of
27
Table of Contents
We have funded our operations primarily with aggregate net proceeds of
approximately
Cash Flows
The following table provides information regarding our cash flows for each of the periods presented (in thousands):
NINE MONTHS ENDEDSEPTEMBER 30, 2022 2021
Net cash used in operating activities
- Net cash provided by financing activities 70 99,604 Net (decrease) increase in cash$ (129,098) $ 82,325
During the nine months ended
During the nine months ended
During the nine months ended
Net Cash Provided by Financing Activities
During the nine months ended
During the nine months ended
28 Table of Contents Funding Requirements
We expect our expenses to increase substantially in connection with our ongoing
research and development activities, particularly as we continue research and
development and advance our THE-630 clinical trial and advance the preclinical
development of our other programs, including THE-349. Furthermore, we expect to
continue to incur additional costs associated with operating as a public company
including increased costs of accounting, audit, legal, regulatory and
tax-related services associated with maintaining compliance with exchange
listing and
Based on our current operating plan, we believe that our cash, cash equivalents,
and investments of
Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on, and could increase significantly as a result of, many factors, including:
the scope, rate of progress, success and costs of our drug discovery,
? preclinical development activities, laboratory testing and clinical trials for
product candidates;
? the number and scope of clinical programs we decide to pursue;
? the scope and costs of manufacturing development and commercial manufacturing
activities for product candidates, if approved;
? the extent to which we acquire or in-license other product candidates and
technologies;
? the timing and amount of any payments required to be made under the agreements
governing acquired or in-licensed product candidates or technologies;
? the cost, timing and outcome of regulatory review of product candidates;
? the cost and timing of establishing sales and marketing capabilities, if any
product candidate receives marketing approval;
the costs of preparing, filing and prosecuting patent applications, maintaining
? and enforcing our intellectual property rights and defending intellectual
property-related claims;
? our ability to establish and maintain collaborations on favorable terms, if at
all;
? the impact of the COVID-19 pandemic or other external disruptions on our
business, results of operations and financial position;
our efforts to enhance operational systems and our ability to attract, hire and
? retain qualified personnel, including personnel to support the development of
product candidates;
? the costs associated with being a public company; and
? the cost associated with commercializing product candidates, if they receive
marketing approval. 29 Table of Contents
A change in the outcome of any of these or other variables with respect to the development of our pan-KIT or EGFR inhibitor programs or any product or development candidate we may develop in the future could significantly change the costs and timing associated with our development plans. Further, our operating plans may change in the future, and we may need additional funds to meet operational needs and capital requirements associated with such operating plans. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings or other capital sources, which could include collaborations, strategic alliances or licensing arrangements. We currently have no credit facility or committed sources of capital. Adequate additional funds may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our existing stockholders may be diluted, and the terms of these securities may include liquidation or other preferences that could adversely affect the rights of such stockholders. Debt financing, if available, may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business.
If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research program or product candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
Contractual Obligations
There have been no significant changes in our contractual obligations and outstanding indebtedness as disclosed in our Annual Report. Refer to Note 7 and Note 8 in our condensed consolidated financial statements included elsewhere in this Quarterly Report for further details.
Critical Accounting Policies and Significant Judgments and Estimates
This management's discussion and analysis is based on our condensed consolidated
financial statements, which have been prepared in accordance with
Emerging Growth Company Status
In
30 Table of Contents
We will remain an emerging growth company until the earliest to occur of: (1)
the last day of the fiscal year in which we have more than
We are also a "smaller reporting company" as defined in the Securities Exchange
Act of 1934, as amended, or the Exchange Act. We may continue to be a smaller
reporting company even after we are no longer an emerging growth company. We may
take advantage of certain of the scaled disclosures available to smaller
reporting companies until the fiscal year following the determination that our
common stock held by non-affiliates is more than
Recently Issued and Adopted Accounting Pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our unaudited condensed consolidated financial statements appearing elsewhere in this Quarterly Report.
© Edgar Online, source